三、分红送配方案情况 不分配不转增 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 4468.19万股，累计占流通股比： 58.17%，较上期变化： -46.26万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 桐乡市顺昌投资有限公司 | 2983.55 | 38.84 | 不变 | | 桐乡中祥化纤有限公司 | 457.12 | 5.95 | 不变 | | 杨绍校 | 370.77 | 4.83 | 196.48 | | HOST VANTAGE ASIA LIMITED | 215.30 | 2.80 | 不变 | | 薛明 | 113.52 | 1.48 | 2.24 | | 邹杰 | 76.80 | 1.00 | 2.03 | | 吕强 | 75.00 | 0.98 | -58.17 | | 周晔 | 63.99 | 0.83 | 不变 | | 袁力 | 56.57 | 0.74 | 新进 | | 李峰 | 55.57 | 0.72 | 新进 | | 较上个报告期退出前十大股东有 | | | ...

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 前十大流通股东累计持有： 34251.77万股，累计占流通股比： 50.61%，较上期变化： -875.37万股。 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2500 | -0.3400 | 173.53 | -0.3000 | | 每股净资产（元） | 5.79 | 5.55 | 4.32 | 5.96 | | 每股公积金(元) | 1.6 | 1.65 | -3.03 | 1.64 | | 每股未分配利润(元) | 2.65 | 2.39 | 10.88 | 2.85 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 16.38 | 16.91 | -3.13 | 19.32 | | 净利润(亿元) | 1.7 | -2.41 | 170.54 | -2.1 | | 净资产收益率(%) | 4.39 | -5 ...

Core Viewpoint - The company is optimistic about the future of the radiation curing industry, driven by technological advancements, policy support, and market expansion opportunities [3][4]. Industry Outlook - Technological advancements in radiation curing, particularly in light curing technology, are expected to drive industry innovation, offering efficiency, cost-effectiveness, and environmental benefits [3]. - The market share of light curing technology in inks and coatings remains low, indicating significant future growth potential [3]. - National policies are supporting the upgrade of the industry by including high-end light initiators and new light curing materials in relevant guidance directories [3]. - The application of light initiators is expanding from traditional printing to high-tech industries such as optoelectronics, information and communication, and 3D printing [3]. Market Competition - The radiation curing industry is experiencing increased production capacity, leading to fierce competition and a supply-demand imbalance, particularly in 2024 [4]. - Major competitors in the light initiator sector include the company, IGM, Jiu Ri New Materials, Qiangli New Materials, and Gurin Technology, with expectations for increased industry concentration [4]. - The company maintains a stable market share due to its comprehensive product series and advanced production technology, despite short-term competition in the dye industry [4]. Company Strategies - The company is optimizing its organizational structure and governance to enhance operational efficiency and integrate its resources effectively [5]. - It is implementing an incentive mechanism linking employee income to production base revenue and profits, aiming to improve profitability [5]. - The company is adjusting its production lines to focus on high-demand products and increasing R&D investment in new products and technologies [5][6]. - It plans to enhance brand recognition and expand into overseas markets to increase its international presence [7]. Financial Performance - In Q1 2025, the company reported a main revenue of 232 million yuan, a year-on-year increase of 74.6%, and a net profit attributable to shareholders of 10.05 million yuan, up 174.81% [9]. - The company's gross profit margin stands at 17.96%, with a debt ratio of 46.42% [9].

同益股份（300538）公告，2024年营业收入30.75亿元，同比下降5.57%。归属于上市公司股东的净亏损 9551.91万元，去年同期净利润2604.55万元，由盈转亏。基本每股收益-0.53元/股。公司计划不派发现金 红利，不送红股，不以公积金转增股本。 ...

前十大流通股东累计持有： 11239.72万股，累计占流通股比： 34.17%，较上期变化： -1136.65万股。 | 名称 持有数量(万股) | | 占总股本比例 (%) | 增减情况(万 | | --- | --- | --- | --- | | | | | 股) | | 东阳华盛企业管理合伙企业(有限合伙) | 4922.83 | 14.96 | 不变 | | 张初全 | 1393.49 | 4.24 | 不变 | | 华懋(厦门)新材料科技股份有限公司回购专用证券 | | | | | 账户 | 1290.16 | 3.92 | 87.66 | | 陈立锋 | 688.45 | 2.09 | -45.43 | | 懋盛(厦门)企业管理咨询有限责任公司 | 659.96 | 2.01 | 新进 | | 林伟斌 | 611.98 | 1.86 | 不变 | | 博时汇兴回报一年持有期混合 | 585.08 | 1.78 | 19.19 | | 东阳华世企业管理合伙企业(有限合伙) | 414.67 | 1.26 | 不变 | | 蓝海荣 | 368.27 | 1.12 | -35.72 | | 诺安成长混 ...

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1500 | 0.2900 | -48.28 | 0.5800 | | 每股净资产（元） | 5.78 | 7.58 | -23.75 | 7.39 | | 每股公积金(元) | 1.86 | 2.72 | -31.62 | 2.72 | | 每股未分配利润(元) | 2.45 | 3.18 | -22.96 | 2.80 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 14.84 | 15 | -1.07 | 17.87 | | 净利润(亿元) | 0.41 | 0.76 | -46.05 | 1.16 | | 净资产收益率(%) | 2.66 | 5.03 | -47.12 | 7.80 | 三、分红送配方案情况 10派0.80元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 18265.84万股，累计占流通股比 ...

Group 1: Industry Outlook - The radiation curing industry is experiencing technological advancements that enhance efficiency, cost-effectiveness, and environmental friendliness, with significant potential for growth in the UV LED light source market [2][3] - National policies are supporting industry upgrades by including high-end photoinitiators and new photopolymer materials in relevant guidance directories, which is expected to drive continuous transformation [3] - The application of photoinitiators is expanding from traditional printing to high-tech industries such as optoelectronics, information and communication, and 3D printing [3] Group 2: Market Competition - The photoinitiator market is currently facing oversupply and intense competition, with the overall market expected to be in a cyclical low in 2024, leading to a gradual balance between supply and demand for certain products [4] - Major competitors in the radiation curing industry include the company, IGM, Jiu Ri New Materials, Qiangli New Materials, and Gurin Technology, with an anticipated increase in industry concentration [4] - The company maintains a stable market share due to advanced production technology and high environmental standards, despite short-term disruptions in the pharmaceutical, pesticide, and dye industries [4] Group 3: Company Strategies - The company is optimizing its organizational structure to enhance governance and integrate resources across seven functional centers, aiming to create a capable team [5] - An incentive mechanism is being implemented to link employee income with revenue and profit from production bases, promoting efficiency and project management [5] - The company is adjusting production lines and focusing on new product development to capture advantageous market segments [5][6] Group 4: Research and Development - The company has invested in R&D, with expenses of 37.6 million, 40.8 million, and 40.4 million over the past three years, maintaining around 5% of revenue [6] - Future R&D efforts will focus on phosphorus-containing flame retardants, new photopolymer products, and pesticide intermediates, with plans to increase production capacity in 2025 [6] Group 5: International Market Expansion - The company's export revenue has been less than 20% of total revenue, with a slight increase expected in 2024 due to global economic conditions [6][7] - The company is actively expanding its overseas market presence through participation in international trade shows and strengthening relationships with distributors and end-users [7] Group 6: Future Development Goals - The company aims to solidify its market position while actively developing in the phosphorus fine chemicals sector, with a strategic goal of becoming a leading supplier of sulfur-phosphorus chemical new materials [7] - The 2025 operational plan includes enhancing strategic decision-making capabilities and focusing on key technological breakthroughs and resource integration [7]

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company has shown steady growth in performance, with significant contributions from its adsorption materials across multiple sectors [5][6] - The company reported a revenue of 2.554 billion yuan in 2024, a year-on-year increase of 3%, and a net profit attributable to shareholders of 787 million yuan, up 10% year-on-year [4][5] - The first quarter of 2025 saw a revenue of 577 million yuan, a decrease of 9% year-on-year, while the net profit attributable to shareholders increased by 14% year-on-year [4][6] Summary by Sections Financial Performance - In 2024, the company's core business revenue (excluding lithium extraction from salt lake systems) was 2.46 billion yuan, a year-on-year increase of 25%, accounting for 96% of total revenue [5] - The revenue from adsorption materials reached 1.99 billion yuan, representing 80.9% of the total revenue, while the revenue from the salt lake lithium extraction project dropped significantly by 81% [5] - For Q1 2025, excluding the salt lake lithium extraction business, the core business revenue was 577 million yuan, a year-on-year increase of 9% [6] Business Segments - The adsorption materials segment has shown high growth across various sectors, with metal resources revenue increasing by 30%, life sciences by 28%, and water treatment and ultrapure water by 34% in 2024 [5] - The life sciences segment is expected to become a core growth engine due to ongoing capacity upgrades and expansions [7] International Strategy - The company has made significant progress in its international strategy, achieving overseas sales revenue of 655 million yuan in 2024, a substantial increase of 45.1% year-on-year [8] - The company is expanding its marketing and technical service network internationally, enhancing its brand influence and reputation [8] Profit Forecast and Valuation - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 1.055 billion yuan, 1.253 billion yuan, and 1.495 billion yuan respectively [9] - The report anticipates continued high growth for the company, particularly in the adsorption materials sector and life sciences [9]

Core Insights - Yongtai Technology (002326.SZ) reported a revenue of 4.589 billion yuan for the year 2024, marking an 11.18% year-on-year increase, while the net profit loss narrowed by 36.26% to -443.87 million yuan, indicating progress in operational efficiency and profitability [1] - The lithium battery materials segment saw an 18.07% revenue growth, with gross margin improving from -28.31% to -5.24%, driven by technological improvements and cost reduction measures [1] - The plant protection segment experienced a significant revenue increase of 91.79%, with gross margin rising by 2.65 percentage points, attributed to successful project launches and recovering downstream demand [1] Revenue and Profitability - The pharmaceutical segment faced a 3.57% revenue decline due to increased market competition and price drops following patent expirations, with gross margin decreasing by 0.77 percentage points [2] - Despite challenges, the company managed to limit the revenue decline through stable partnerships and market expansion strategies [2] Technological Advancements - Yongtai Technology has established a dual-channel development strategy in the pharmaceutical sector, focusing on high-value and stable raw materials and formulations [3] - The company’s subsidiaries achieved significant regulatory milestones, including FDA inspections and drug registration certificates, enhancing its market expansion capabilities [3] Production and Operational Efficiency - The company is focusing on core project development and optimizing its industrial chain layout to achieve economies of scale, with a lithium project entering trial production [4] - Yongtai Technology's lithium battery electrolyte shipment volume has entered the top ten in China, reflecting improved market competitiveness [4] Market Position and Collaborations - The company has formed long-term partnerships with major firms like Merck and BASF, strengthening its market position [2] - Yongtai Technology is leveraging overseas pesticide registration resources to expand its market share in the plant protection sector [4] Research and Development - The company has established R&D centers in Zhejiang and Shanghai, with an AI-driven drug development platform enhancing its research capabilities [5] - Yongtai Technology has successfully transformed multiple research outcomes into production, optimizing processes and reducing costs [6] Intellectual Property and Innovation - The company has applied for a total of 221 invention patents, with 171 granted, emphasizing its commitment to intellectual property protection [6] - The year 2024 is characterized by significant advancements across various sectors, reinforcing the company's competitive edge through innovation and market expansion [6]

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 11867.38万股，累计占流通股比： 23.36%，较上期变化： 632.89万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1085 | -0.1323 | 182.01 | -1.4372 | | 每股净资产（元） | 2.51 | 2.54 | -1.18 | 2.67 | | 每股公积金(元) | 2.25 | 2.25 | 0 | 2.25 | | 每股未分配利润(元) | -0.85 | -0.96 | 11.46 | -0.83 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 19.4 | 19.69 | -1.47 | 29.17 | | 净利润(亿元) | 0.55 | -0.68 | 180.88 | -7.42 | | 净资产收益率(%) | 4.24 | - ...